226 related articles for article (PubMed ID: 16973089)
1. Breast cancer (metastatic).
Stebbing J; Crane J; Gaya A
Clin Evid; 2006 Jun; (15):2331-59. PubMed ID: 16973089
[No Abstract] [Full Text] [Related]
2. Breast cancer (metastatic).
Stebbing J; Glassman R
Clin Evid; 2005 Jun; (13):2197-225. PubMed ID: 16135325
[No Abstract] [Full Text] [Related]
3. Breast cancer (metastatic).
Stebbing J; Glassman R
Clin Evid; 2004 Jun; (11):2266-99. PubMed ID: 15652111
[No Abstract] [Full Text] [Related]
4. Breast cancer (metastatic).
Johnston S; Stebbing J
Clin Evid; 2003 Dec; (10):1975-2002. PubMed ID: 15555190
[No Abstract] [Full Text] [Related]
5. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
6. New options in the prevention and treatment of breast carcinoma.
Galleshaw J
J Med Assoc Ga; 2003; 92(1):19-22. PubMed ID: 12743901
[No Abstract] [Full Text] [Related]
7. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
8. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
9. Future directions in endocrine treatment of advanced breast cancer.
Bland KI
Ann Surg Oncol; 1999 Dec; 6(8 Suppl):14S-16S. PubMed ID: 10619455
[No Abstract] [Full Text] [Related]
10. Breast cancer (non-metastatic).
Rodger A; Stebbing J; Thompson AM
Clin Evid; 2006 Jun; (15):2360-92. PubMed ID: 16973090
[No Abstract] [Full Text] [Related]
11. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Kahán Z
Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
[No Abstract] [Full Text] [Related]
12. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid prevents cancer treatment-induced bone loss.
Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
[No Abstract] [Full Text] [Related]
14. Breast cancer: adjuvant modalities.
Sakr BJ; Dizon DS
Clin Obstet Gynecol; 2011 Mar; 54(1):150-6. PubMed ID: 21278514
[TBL] [Abstract][Full Text] [Related]
15. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
16. A better medication for treating breast cancer?
Johns Hopkins Med Lett Health After 50; 2002 May; 14(3):3. PubMed ID: 12004835
[No Abstract] [Full Text] [Related]
17. Alternative to tamoxifen effective for preventing breast cancer recurrence.
Mayo Clin Womens Healthsource; 2005 May; 9(5):3. PubMed ID: 15891689
[No Abstract] [Full Text] [Related]
18. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
Ryan PD; Goss PE
Nat Clin Pract Oncol; 2005 Dec; 2(12):596-7. PubMed ID: 16341095
[No Abstract] [Full Text] [Related]
19. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
20. Remission of macroglobulinemia during anastrozole treatment for breast cancer.
Chettle C; Baker MA
N Engl J Med; 2005 Apr; 352(16):1725-6. PubMed ID: 15843681
[No Abstract] [Full Text] [Related]
[Next] [New Search]
